+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Not Verified

COiMMUNITY Initiative

GlaxoSmithKline

GSK awards $2M in COiMMUNITY Initiative grants to help close vaccination gaps, commits $3M for 2026

• Sixteen organizations, awarded funding in 2025, are taking innovative, local approaches to boosting vaccination in communities across the US

• Grant recipients’ projects aim to modernize outreach campaigns, strengthen immunization systems and mobilize advocates to keep prevention top of mind

• Increased funding is available for 2026, with applications now open for projects supporting vaccination for people of all ages

GSK plc (LSE/NYSE: GSK) today announced the 2025 recipients of its COiMMUNITY Initiative grant program, awarding a total of $2 million across 16 state, regional and national non-profits working to improve immunization rates across the US. Through COiMMUNITY, GSK invests in local efforts to improve vaccine education and uptake. Now in its third year, the Initiative will offer $3M in grants supporting projects that improve vaccine communication and delivery for people of all ages.

Leonard Friedland, Vice President, Scientific Affairs and Public Health, Vaccines, GSK, said: “Each of these organizations is addressing barriers to immunization from a different angle—supporting healthcare teams, improving infrastructure and engaging communities. What connects them is their shared goal of keeping prevention at the forefront of the conversation and turning purpose into action.”

Among the 2025 grantees is The J.A.M.I.E. (Joint Advocacy of Meningococcal Information & Education) Group, which is using COiMMUNITY funds to expand advocacy and education around meningococcal disease, also known as meningitis, an uncommon but potentially life-threatening illness. Even with treatment, about 1 in 10 people who get meningitis die from it, and 1 in 5 develop long-term disabilities.1 College-age young adults are among the highest risk age groups for meningitis. 2

Jamie and Patsy Schanbaum, Cofounders, The J.A.M.I.E. Group, said: “Meningitis can change lives in a matter of hours and in ways most people can’t imagine. Yet, it’s vaccine preventable. With this funding support, we’re planning to work with city and state officials in New York to raise awareness of meningitis prevention.”

Another organization, Immunize Colorado, is using behavioral science to train healthcare providers, health educators, front desk staff and public health professionals on how to effectively talk about vaccines in their day-to-day encounters.

Susan Lontine, Executive Director, Immunize Colorado, said: “We’re meeting healthcare teams where they are: busy, stretched and trying to do the right thing for their patients. Our grant-funded program focuses on short, skillsbased sessions to help providers guide conversations about vaccines with confidence and empathy, giving them a framework for listening first, responding to concerns and helping their patients make informed choices about vaccination.”

Other awardees for 2025 include the American College of Physicians, American Heart Association, American Lung Association, American Pharmacists Association, Arkansas Immunization Action Coalition, Association of Immunization Managers, Health Betterment Initiative, Indiana Immunization Coalition, National Council on Aging, Pennsylvania Pharmacists Association, Sepsis Alliance, The Arizona Partnership for Immunization, UNITY Consortium and Voices for Vaccines.

Call for 2026 COiMMUNITY Initiative Grant Proposals In 2026, GSK will award $3 million in COiMMUNITY Initiative grants to support ambitious and actionable efforts to increase US adult immunization rates through vaccine education, outreach and access. Eligible organizations can now submit a proposal through gskgrants.com. Please address your letter of request to the COiMMUNITY Initiative. GSK will review grant proposals on a rolling basis until mid-November 2026.

About the COiMMUNITY Initiative Launched in 2023, GSK’s COiMMUNITY Initiative aims to address barriers to immunization in the US through two pillars: grant funding and increased data transparency through Vaccine Track. To date, GSK has awarded $5 million to nonprofits and community groups working to expand vaccine awareness and access nationwide. Vaccine Track -- a firstof-its-kind interactive tool -- provides real-time adult immunization data to inform decisions and strengthen public health strategies. By combining funding, data insights and on-the-ground learnings, COiMMUNITY is driving sustainable solutions to close vaccination gaps for people of all ages.

AI Based Application Success Predictor

🔑 1. Strong Alignment with GSK Therapeutic Areas (Top Predictor)

GSK funding is tightly aligned with its R&D focus:

Vaccines
Infectious diseases
Oncology
Immunology / respiratory diseases

👉 Proposals outside these areas have very low success probability

🔄 2. Clear Relevance to GSK Products or Pipeline (Critical)

Many funded studies:
- Use GSK medicines, vaccines, or compounds
- Evaluate real-world use, safety, or new indications

👉 GSK may provide:

Funding
Study drug/product
Or both

👉 Strong “product or pipeline relevance” is often decisive

🧪 3. High Scientific Merit & Methodological Rigor

Proposals must demonstrate:
- Clear hypothesis
- Robust study design
- Ethical and regulatory compliance

👉 External investigators are fully responsible for study quality and conduct

🏥 4. Clinical or Translational Focus (Major Predictor)

GSK strongly favors:

Clinical trials (Phase I–IV)
Observational or real-world studies
Translational research linked to patient outcomes

👉 Pure theoretical/basic research is less competitive

🤝 5. Investigator Independence & Capability

Studies are:
- Designed and led by external investigators
Investigator must show:
- Ability to conduct high-quality, ethical research
- Institutional support

👉 Sponsor (investigator) is accountable for all aspects of the study

📊 6. Alignment with “Areas of Interest” (AOIs)

GSK publishes:
- Specific research priorities / calls
Proposals aligned with these AOIs:
- Have significantly higher success rates

👉 Off-topic proposals are rarely considered

🌍 7. Global Health Impact (Especially for Grants)

For non-ISS grants:

Priority areas include:
- Infectious diseases
- LMIC health challenges

👉 Strong emphasis on public health impact in global health programs

🚀 8. Innovation with Practical Application

Preference for:
- Studies improving treatment strategies
- New uses of existing therapies
- Implementation science

👉 Innovation must be clinically meaningful

📈 9. Feasible, Protocol-Ready Study Design

If selected:
- Applicants must submit a full protocol quickly (~5 weeks)
Requirements include:
- Clear endpoints
- Timeline
- Deliverables

👉 Feasibility is critical for approval

💰 10. Transparent Budget & Compliance

Budget must meet:
- Fair market value standards
Strict requirements:
- Ethical approval
- Legal agreements
- Reporting obligations

👉 Non-compliance leads to rejection

📊 Summary: Key Predictors (Ranked)

Highest impact factors:

Alignment with GSK therapeutic areas
Relevance to GSK products/pipeline
Clinical/translational focus

Moderate predictors:
4. Scientific rigor
5. Alignment with Areas of Interest (AOIs)
6. Investigator capability

Supporting factors:
7. Global health relevance
8. Innovation with application
9. Feasibility & protocol readiness

💡 Insider Insight

Compared to other pharma funders:

GlaxoSmithKline is:
👉 highly structured + compliance-driven
👉 product- and evidence-generation focused

👉 Key evaluation question:
“Will this study generate valuable clinical or scientific evidence related to GSK’s therapies or priorities?”

Product relevance ✔️
Strong clinical design ✔️
Clear implementation pathway ✔️
→ Highest success probability

Specialties

Immunology

Public Health

Eligibility Requirements

COiMMUNITY Initiative grants to support ambitious and actionable efforts to increase US adult immunization rates through vaccine education, outreach and access.

Sponsor Details

Sponsor Institute/Organizations: GlaxoSmithKline

Sponsor Type: Corporate/Non-Profit

Address: 2929 Walnut Street Ste. 1700 Philadelphia, PA 19104

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity